ANGO logo

ANGIODYNAMICS INC

ANGONASDAQ
πŸ† #2296 by market capEarnings Sep 30US Equity
$15.73β–Ό $0.01 (βˆ’0.06%)
Market closed Β· at close
1hβ€”
24hβ–Ό 0.1%
7dβ–² 4.5%
14dβ–² 7.8%
30dβ–² 23.4%
1yβ–² 77.7%
🏦Market Cap
$650M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+9.5%
Slowing
πŸ“ŠGross Margin
54.6%
Healthy
πŸ’΅FCF Margin
6.6%
Moderate
βš–οΈP/S Ratio
2.0x
Cheap
Otter Score
44
Weak

Trading Snapshot

Day Range
$15.68 – $15.98
52-Week Range
$8.36 – $16.05
Volume
$2.73B
Avg Volume
$2.23B
Shares Outstanding
41.3M
Next Earnings
Oct 25, 2026

Fundamentals Snapshot

Annual Revenue
$320M
Last Q Revenue
$87M
P/E Ratio
β€”
P/S Ratio
2.0x
EPS (TTM)
$-0.89
Dividend Yield
β€”

Why Investors Own ANGO

  • βœ“High-growth profile β€” revenue up +59.2% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 33% gross margin and 13% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$320Mβ–² +65.8% YoY
Gross Margin (TTM)
33.2%β–² +0.0% YoY
Operating Income (TTM)
$93Mβ–² +65.8% YoY
Free Cash Flow (TTM)
$40Mβ–² +65.8% YoY

About ANGIODYNAMICS INC

AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
44/100

Analyst Price Target

β“˜
Average Target
$19.84
β–² +26.1% Upside
High Target$24.87
Low Target$15.60
Based on 34 analysts

Latest News & Updates